Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
about
Identifying source proteins for MHC class I-presented peptides.Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in miceImmunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccineTelomerase-based immunotherapy of cancer.Telomerase immunity from bench to bedside: round one.Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response.HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.Prospects and challenges of building a cancer vaccine targeting telomeraseThe functioning antigens: beyond just as the immunological targets.Novel approaches in polyepitope T-cell vaccine development against HIV-1.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic miceImmunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.Tumor-associated antigens for specific immunotherapy of prostate cancer
P2860
Q34553385-17932072-41F8-4683-8D75-E71D516AA69CQ35184204-52A1E2EE-0644-46CC-ABE3-8B65550BEE4BQ35326248-6D6537F1-2178-4442-AA43-26D95179E87AQ36600251-43D061D0-87FF-45D0-B6C4-3708DCA58F66Q36745749-5F79C330-CE4D-43D4-8084-90687410E4E5Q36821063-6BA240E5-B090-4851-B55E-482CD9F53F93Q36840281-E6DA390D-32B7-4913-9F26-AC4C1B21F34DQ36918394-AB329435-58EB-4250-AC07-3DA101E29B22Q37483795-6C940D8F-71F2-4C77-A0F5-53FD16B5F0B5Q38168900-40376A68-A3A7-434B-B1B8-D956EE5C514BQ38625948-20B594FB-94DB-4D73-B25C-5002CDDA4A6EQ38706572-3668759A-DE08-429E-82BB-43C80AA71700Q39205106-95F0DF65-1B43-4F1D-A9AB-612FC7AA9D86Q41541911-A74C8896-E10E-41EF-9C03-7B60BF92A624Q41935730-08A1BF90-88DA-4DBD-8724-FDAE2B0CE8CFQ41977894-96511DE6-3F6B-4239-8E38-FB4BF40E4534
P2860
Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Immunogenic HLA-B*0702-restric ...... or cytotoxic T-cell responses.
@en
type
label
Immunogenic HLA-B*0702-restric ...... or cytotoxic T-cell responses.
@en
prefLabel
Immunogenic HLA-B*0702-restric ...... or cytotoxic T-cell responses.
@en
P2093
P1476
Immunogenic HLA-B*0702-restric ...... mor cytotoxic T-cell responses
@en
P2093
Blandine Mignen
Christine Neuveut
Emmanuelle Boulanger
François Lemonnier
Karine Mollier
Maurizio Zanetti
Olivier Adotévi
Pierre Charneau
Pierre Langlade-Demoyen
Sylvain Cardinaud
P304
P356
10.1158/1078-0432.CCR-05-2647
P407
P577
2006-05-01T00:00:00Z